23 results
424B5
ARQT
Arcutis Biotherapeutics Inc
1 Mar 24
Prospectus supplement for primary offering
4:06pm
ability to drive prescriber awareness and use, patient engagement and positive experience with ZORYVE cream, and our efforts to establish broad, high … our early commercialization efforts and patient engagement. Market research points to an increasing preference among dermatologists to prescribe
424B5
ARQT
Arcutis Biotherapeutics Inc
28 Feb 24
Prospectus supplement for primary offering
4:21pm
written as of February 16, 2024. We believe this growth is due to our ability to drive prescriber awareness and use, patient engagement and positive … significant growth in refill prescriptions in the second half of 2023 following our early commercialization efforts and patient engagement. Market research
424B5
ARQT
Arcutis Biotherapeutics Inc
23 Oct 23
Prospectus supplement for primary offering
4:23pm
this growth is due to our ability to drive prescriber awareness and use, patient engagement and positive experience with ZORYVE, and our efforts
424B5
3oo2t mdk
19 Oct 23
Prospectus supplement for primary offering
4:15pm
8-K
EX-99.1
gz3bjk
19 Oct 23
Results of Operations and Financial Condition
4:02pm
DEF 14A
z0s5vopiqwe9chsu60
27 Apr 21
Definitive proxy
4:54pm
10-K
6dxl9 s19hd50
19 Mar 20
Annual report
4:47pm
424B4
wwfk el9pe9cuigcj
31 Jan 20
Prospectus supplement with pricing info
5:25pm
S-1/A
vfki62ke67ns63v
21 Jan 20
IPO registration (amended)
9:08am
S-1
65zeoez4co2fkyydndtf
6 Jan 20
IPO registration
12:21pm
S-1
EX-3.3
jloro ae2y
6 Jan 20
IPO registration
12:21pm
DRS/A
oiwq jp1wk
13 Dec 19
Draft registration statement (amended)
12:00am
DRS/A
0ze14
12 Nov 19
Draft registration statement (amended)
12:00am